NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALSJosé Jiménez-Villegas(Hospital La Paz Institute for Health Research), Ana I. Rojo(Biomedical Research Networking Center on Neurodegenerative Diseases)Free Radical Biology and MedicineJuly 24, 202110.1016/j.freeradbiomed.2021.07.022Cited by 43SaveCiteExport RISWatch citationsRelated PapersDipeptide Repeat Pathology in C9orf72-ALS Is Associated with Redox, Mitochondrial and NRF2 Pathway Imbalance|Antioxidants|2022|17